FDA Antidepressant Birth Defect Warnings
The FDA has issued warnings about antidepressant related birth defects:
- December 2005: The FDA warned that studies have shown that infants born to women who had first trimester paroxetine exposure had an increased risk of cardiovascular malformations, primarily ventricular and atrial septal defects (VSDs and ASDs). According to birth defect attorneys and a study published in the New England Journal of Medicine, women who take these anti-depressant drugs during pregnancy quadruple the risk of their babies experiencing a septal heart defect.
- July 2006: The FDA warned that pregnant women exposed to SSRIs late in the third trimester (after their 20th week) have reported developing PPHN – breathing and lung problems. According to birth defect attorneys, the same study reported that the risk of PPHN is six times greater for women who take anti-depressant drugs during pregnancy than for women who haven’t taken anti-depressants during pregnancy.
